<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT933-14446</title>
	</head>
	<body>
		<main>
			<p>930714 FT  14 JUL 93 / UK Company News: Maiden profit at ML Labs ML LABORATORIES, the USM-quoted research and development company which has the dialysis drug Icodextrin as its main product, turned in pre-tax profits of Pounds 65,000 for the six months to March 31. The outcome, the company's first profit since its shares were placed at 70p on the Third Market in 1987, compared with a deficit of Pounds 447,000. Turnover was up at Pounds 467,000 (Pounds 312,000) and earnings per share came out at 0.1p against losses of 1.8p. At the year-end the company had Pounds 14.8m on deposit. Following the announcement that it had won a marketing licence for Icodextrin in January, the shares - which moved to the USM in December 1990  -jumped to their present level of about Pounds 11, giving a market capitalisation of more than Pounds 300m. Icodextrin is a drug which can be used in chemical dialysis so that kidney patients do not have to rely on hospital visits to use kidney machines but can change bags of fluid in their own abdomen themselves, at home or at work. The estimated market for Icodextrin - which makes it possible for patients to go for longer in between fluid changes and has fewer side effects than other drugs - is, according to Mr Stuart Sim, finance director, 'conservatively estimated at Pounds 487m a year.'</p>
		</main>
</body></html>
            